Nested Therapeutics’ Post

Very happy to be in San Diego to attend the Annual meeting of the American Association for Cancer Research AACR 2024 April 5-10. We will be missing the Solar Eclipse but experiencing stellar presentations! We will be presenting two posters featuring Precision Antibody technology of developing fully human monoclonal antibodies using humanized transgenic mice. One poster on April 8th will feature the new generation of fully human anti-progranulin antibodies and their effect on triple negative breast cancer cells and non-small cell lung carcinoma, poster session 22 number 8. The second poster will be presented April 9th poster session 28 number 15 will feature the effect of fully human anti-PTGFRN drug conjugate on head and neck cancers. #antibodies #ADC #lung cancer #breast cancer #head and neck, #AACR

Getting ready for the #ASCO24 experience in Chicago! Who else is joining? Join me and the Genomate Health team as we present our latest findings, especially our new evidence on the predictive power of the Genomate (DDA) score for immune checkpoint therapy and targeted therapy responses in lung cancer. If you're interested in discussing our work or exploring potential collaborations, I'd love to connect! #PrecisionOncology #CancerResearch #GenomateatASCO24

Impact of the FIGO 2023 staging system for endometrial cancer in a large cohort from an Italian referral center. Background In 2023, the FIGO Women’s Cancer Committee released a novel staging system. The newly introduced system transitioned from a dissemination-based approach to one encompassing prognostic factors such as histotype, grading, and lymphovascular space invasion (LVSI). Additionally, the integration of molecular classification, when available, is a key feature of this updated system. This study aims to describe the application of the new staging system in a large population from a referral center. ------------------------------------------------------------------------------ Conclusion The new FIGO staging system has considerably reshaped the classification of endometrial cancer. Updated guidelines on the adjuvant treatment integrating this novel staging system are expected to apply it into the clinical practice

As we close off the year, we look back on our ongoing partnership with Peter MacCallum Cancer Centre, a collaboration that has stretched over the past 2 years and has positively influenced the realm of cancer research and treatment. Through this partnership, CellVec has played a pivotal role in ensuring a stable supply of critical research and GMP grade lentiviral vectors, essential components for the success of PeterMac’s Centre of Excellence in Cellular Immunotherapy Clinical Trial Development Program. We are manufacturing and supplying these vectors for their in-house pipeline of novel cell-based immunotherapies, contributing to the accelerated development of much-needed cancer therapies, especially in the face of the ongoing global shortage of lentiviral vectors. As we celebrate these two years of progress, we remain committed to driving innovation in the field of healthcare and look forward to further advancements in our shared mission to enhance cancer treatment. #ThrowbackThursday #CancerResearch #HealthcarePartnership #Innovation

We are excited to share that our collaborators, the Mayo Clinic and Johns Hopkins Medicine, will be presenting key data at the American Association for Cancer Research’s Annual Meeting 2024, in San Diego, California. These data underscore the therapeutic potential of Step Pharma’s leading cytidine triphosphate synthase 1 (CTPS1) selective inhibitor STP938. The presentations will focus on the therapeutic potential of CTPS1 inhibition in breast, ovarian and prostate cancer. The Mayo team demonstrate that CTPS1 inhibition may be effective in breast and ovarian cancer. The JHM team identify CTPS1 as a synthetic vulnerability in supraphysiological androgen treated prostate cancer. STP938 could represent a treatment option in the future for patients with any of these three types of cancer. At Step Pharma we are looking to drive a step change in the treatment of cancer with STP938, our targeted cancer therapy, currently in clinical trials for T cell and B cell lymphoma. Find out more here: https://lnkd.in/g6P3g2CD #AACR #biotech #oncology #drugdiscovery  

June marks the beginning of Cancer Immunotherapy Month, an annual campaign we are proud to support. Gera Goverse, Director, Immuno-Oncology, gives her reflections on cancer immunotherapy as an innovative approach, offering new hope and possibilities for patients worldwide. At Crown Bioscience, our mission is to empower our customers to improve human health. We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation. We are utilizing our large patient-derived organoid biobank, which includes almost 100 models validated in co-culture assays with immune cells, so newly developed immunotherapies can be tested preclinically. These models thereby contribute to the improvement of clinical success of cancer patients. Join us this month as we continue to share recent advancements, preclinical resources, and explore the future of cancer immunotherapy together. Learn more about us ➡️https://hubs.la/Q02zhZDt0 #Immunotherapy #Immune2Cancer #CancerResearch Cancer Research Institute (CRI)

Colon cancer is the leading cause of cancer death in men younger than 50 years of age(1)– but CheckIt4Andretti and Polymedco are committed to preventing more deaths and saving more lives through early detection. 90% of colon cancer deaths are preventable when caught early(2), which is why our organizations are joining forces to increase access to expert-recommended screening solutions, including annual FIT with OC-Auto FIT. Learn more about annual screening with OC-Auto FIT by following Polymedco or visiting cancerscreens.com. 1.Colorectal cancer facts & figures 2023-2025. American Cancer Society. Accessed January 25, 2023. https://lnkd.in/exkWqmrP... 2. Tepus M, Yau TO. Non-invasive colorectal cancer screening: an overview. Gastrointest Tumors. 2020;7(3):62-73. doi:10.1159/000507701

In a recent study co-authored by Dr. Stepan Nersisyan, a former research supervisor at ABI, researchers have uncovered crucial insights into how different forms of a protein called CD44 impact the progression and spread of colorectal cancer (CRC). These insights may lead to more targeted treatments, offering hope for better outcomes for CRC patients. 🔬 Isoform 4 of CD44 is associated with poorer outcomes and increased cancer cell spreading, while isoform 3 appears to act as a protective factor. 🛡️ A noteworthy finding: Lowering CD44 levels in lab cells not only slowed down the main tumor growth but also strikingly halted cancer spread (metastasis) in experiments. ❗ The study suggests that isoforms 3 and 4 are more active in low-oxygen tumor areas, hinting at a connection between the protein and the cancer environment. In simpler terms, this research clarifies how CD44 influences colorectal cancer behavior. 🔎🧬 Read the paper - https://lnkd.in/eTFy94um

Embracing cancer complexity: Hallmarks of a systemic disease As #Cell marks its 50th anniversary, Cell Press has brought together leading voices in cancer research to shed light on the evolution of our understanding of #cancer over the past five decades. Explore this landmark discussion here: "https://lnkd.in/ev-i6hbh The section "Future strategies aimed to leverage cancer complexities" offers a thought-provoking perspective. It remarks that traditional strategies, which inhibit pathways driving cancer cells, often lead to further oncogenic alterations, drug resistance, and more malignant cancer cells. This observation raises the question of whether therapeutic overactivation of these pathways - also harmful to cancer cells - could force cancer cells to diminish oncogenic signaling, redirecting them towards less malignant forms. This notion is supported by our recent research. Read our findings in AACR Journals Cancer Discovery: https://lnkd.in/dzh_-Xbz Although this strategy presents unique challenges and risks, it opens promising avenues for directing cancer cells toward less aggressive behaviors, offering new hope for future cancer therapies.

🗓️ Today is World Pancreatic Cancer Day! 🟣 Pancreatic Cancer is the 7th most deadly form of cancer. It’s considered to be one of the most difficult cancers to treat due to its insidious symptoms and high degree of malignancy, leading to a high mortality rate. In line with our #Servier2030 ambitions, the fight against cancer is one of our strategic priorities. We’re committed 💪 to targeting hard-to-treat cancers that have limited treatment options. We have further strengthened our cancer research ecosystem with Symphogen, our center of excellence for monoclonal antibodies in Denmark 🇩🇰, and our R&D center in the U.S. 🇺🇸 focused on developing innovative cancer treatments. Learn more about our commitments 👉 https://lnkd.in/e7sqNQMV #WPCD #WorldPancreaticCancerDay #PancreaticCancer #oncology #innovation #patient #MovedByYou #ItsAboutTime